In addition to non-compressible torso hemorrhage in trauma, data continues to accumulate for the COBRA-OS®, the smallest aortic occlusion device on the market, in other applications such as in the management of one of the most difficult causes of postpartum hemorrhage, placenta accreta.
LONDON, ON, Oct. 31, 2023 /PRNewswire-PRWeb/ -- Front Line Medical Technologies, Inc., a Canadian based medical device company, announced that the first real-world postpartum hemorrhage data using their groundbreaking aortic occlusion device, the COBRA-OS®, was presented this past month at the Pan-American Society for the Placenta Accreta Spectrum 5th Annual Meeting, hosted by Stanford University. In two separate abstract presentations from two high volume US obstetrical referral centers, the positive results of prophylactic aortic occlusion during high-risk placenta accreta cases with the COBRA-OS® were presented. Both Texas Children's Hospital, Baylor College of Medicine, in Houston, Texas, and Atrium Health, Wake Forest Baptist Medical Centre, have adopted the COBRA-OS® for many of their high-risk placenta accreta patients. Front Line applauds the investigators from these institutions for this encouraging data and for their pioneering efforts in treating this difficult patient population. Currently the device is also being used throughout the US and Canada in major trauma centers and within the US military to help with noncompressible torso hemorrhage from trauma.
"Helping mothers survive high-risk deliveries is a major focus of our company with the innovative COBRA-OS®," said Front Line co-founder Adam Power, MD, a practicing vascular surgeon. "In female patients who are at higher risk of clotting due to pregnancy and who have smaller arteries, it is critical to use a low-profile aortic occlusion device to avoid the complications seen with larger devices. With no reported access site complications in either of these studies, we are seeing yet again the increased safety of the COBRA-OS®."
"This real-world, non-industry sponsored data showed significant reductions in blood loss and transfusion requirements in one study and was helpful when used in a selective hemorrhage control strategy in the other," stated co-founder and CEO Asha Parekh, PhD. "In addition, one of the studies demonstrated the utility of the COBRA-OS® for intermittent and partial REBOA applications as well."
The Pan-American Society for the Placenta Accreta Spectrum meeting is typically held in October, which coincides with Accreta Awareness Month (AAM). AAM encourages patients, survivors, medical professionals and public health advocates to spread the word about increased rates and risk factors associated with placenta accreta. At this year's meeting, the COBRA-OS® was featured in a hands-on workshop led by Dr Adam Power, who is also the chief medical officer of Front Line. The conference was attended by high-risk obstetrical specialists from across North America.
"Postpartum hemorrhage is a tragically underrecognized global health crisis," Dr Parekh continues. "For the many mothers who suffer from these devastating complications, this positive data helps us to spread the word about innovative solutions for some of the world's biggest health problems".
For more information on the Pan-American Society for the Placenta Accreta Spectrum, please visit https://www.passquared.org/ and for more information on Accreta Awareness Month, please visit the National Accreta Foundation at https://www.preventaccreta.org/
The COBRA-OS® gained FDA clearance and Health Canada approval in 2021 and the company is also pursuing clearance in Europe and other countries around the world.
About Front Line Medical Technologies: Front Line Medical Technologies is a Canadian medical device company based in London, Ontario. Front Line is led by a unique team who are passionate about lowering the barriers to bleeding control and resuscitation worldwide. For more information about Front Line and the COBRA-OS® visit FrontLineMedTech.com
Media Contact
Seema Gogna, Front Line Medical Technologies, 1 905-251-4248, [email protected], www.frontlinemedtech.com
SOURCE Front Line Medical Technologies
Share this article